The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2−) breast cancer: When might multigene assays be of value?

Research output: Contribution to journalArticle

Authors

  • Matti Aapro
  • Michelino De Laurentiis
  • Juan Enrique Bargallo Rocha
  • Roberto Elizalde
  • László Landherr
  • Barbro Linderholm
  • Eleftherios Mamounas
  • Christos Markopoulos
  • Patrick Neven
  • Alexander Petrovsky
  • Roman Rouzier
  • Vincent Smit
  • Christer Svedman
  • Daniel Schneider
  • Christoph Thomssen
  • Miguel Martin

Colleges, School and Institutes

External organisations

  • Genolier Breast Center
  • National Cancer Institute G. Pascale Foundation
  • Instituto Nacional de Cancerología
  • Hospital Dr. I. Pirovano
  • Uzsoki Teaching Hospital
  • Karolinska Univ Hospital
  • Florida International University
  • Athens University Medical School
  • Leuven Cancer Institute
  • N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
  • Institut Curie
  • Leiden University Medical Center - LUMC
  • Medical Affairs
  • International Center
  • Martin-Luther University Halle-Wittenberg
  • Universidad Complutense de Madrid

Abstract

Background

A modest proportion of patients with early stage hormone receptor-positive (HR+), HER2-negative (HER2−) breast cancer benefit from adjuvant chemotherapy. Traditionally, treatment recommendations are based on clinical/pathologic criteria that are not predictive of chemotherapy benefit. Multigene assays provide prognostic and predictive information that can help to make more informed treatment decisions. The MAGIC survey evaluated international differences in treatment recommendations, how traditional parameters are used for making treatment choices, and for which patients treating physicians feel most uncertain about their decisions.

Methods

The MAGIC survey captured respondents' demographics, practice patterns, relevance of traditional parameters for treatment decisions, and use of or interest in using multigene assays. Using this information, a predictive model was created to simulate treatment recommendations for 672 patient profiles.

Results

The survey was completed by 911 respondents (879 clinicians, 32 pathologists) from 52 countries. Chemo-endocrine therapy was recommended more often than endocrine therapy alone, but there was substantial heterogeneity in treatment recommendations in 52% of the patient profiles; approximately every fourth physician provided a different treatment recommendation. The majority of physicians indicated they wanted to use multigene assays clinically. Lack of reimbursement/availability were the main reasons for non-usage.

Conclusions

The survey reveals substantial heterogeneity in treatment recommendations. Physicians have uncertainty in treatment recommendations in a high proportion of patients with intermediate risk features using traditional parameters. In HR+, HER2− patients with early disease the findings highlight the need for additional markers that are both prognostic and predictive of chemotherapy benefit that may support more-informed treatment decisions.

Details

Original languageEnglish
Pages (from-to)191-199
Number of pages9
JournalThe Breast
Volume33
Early online date22 Apr 2017
Publication statusPublished - 1 Jun 2017

Keywords

  • Adjuvant chemotherapy, HER2-negative early breast cancer, Hormone receptor-positive, Multigene assay, Treatment decision

ASJC Scopus subject areas